Probiotic Skin Treatments Show Promise for Acne, Five-Trial Review Finds

If you have cycled through benzoyl peroxide, retinoids, and maybe a course of antibiotics for stubborn acne, and you still deal with breakouts, or with the dryness and irritation those treatments can bring, you have probably wondered whether a gentler option exists. A wave of skincare products now claims to fight acne by rebalancing the skin's bacterial community instead of blasting it. A new systematic review, published in Eksakta: Berkala Ilmiah Bidang MIPA, pulled together the actual human clinical evidence behind these products, five trials in total, to separate what has been tested in people from what is still marketing.

Key takeaways

• Five human clinical trials found topical postbiotics, probiotic-derived lotions, and a bacteriophage gel reduced acne lesions, oil production, or acne-causing bacteria.
• One probiotic-derived lotion matched benzoyl peroxide's inflammatory-lesion improvement with fewer side effects, the closest any product came to beating the standard treatment.
• The catch: all five trials were small (45 to 104 people), mostly ran just three to four weeks, and none proved these products are superior to existing acne therapy.

Topical Postbiotics and a Bacteriophage Gel Reduced Acne Lesions in Five Human Trials

A systematic review of five clinical studies published between 2020 and 2025 found that topical products designed to modulate the skin microbiome (the community of bacteria that lives on skin) produced measurable improvements in acne lesions, oil production, or acne-causing bacteria in every trial included, though none has yet been shown to outperform standard acne treatment. The largest effect came from an open-label study of a postbiotic (a preparation of inactive microorganisms or their byproducts that still triggers a biological effect, as opposed to a probiotic, which uses live organisms) called LactoSporin, a 2% cream that cut sebum, or skin oil, by 42.4%, from 106.74 to 61.41 micrograms per square centimeter, after 21 days, alongside reductions of 63.11% in open comedones (blackheads), 50.02% in closed comedones (whiteheads), 69.96% in papules, and 83.02% in pustules (p < 0.0001). A separate lotion built on a Lactiplantibacillus plantarum ferment lysate improved lesions in 59.1% of participants and cut sebum in 72.7% by week four. And a lotion derived from Lactobacillus paracasei MSMC 39-1 produced inflammatory-lesion improvement comparable to 2.5% benzoyl peroxide, the standard topical treatment, in a 104-person randomized trial, with fewer side effects (7.69% versus 26.92%).

Nearly 10% of People Aged 10 to 24 Worldwide Deal With Acne

Acne vulgaris affected an estimated 9.79% of people aged 10 to 24 worldwide in 2021, with the heaviest toll falling on 15-to-19-year-olds, according to global burden data the review cites from a 2025 British Journal of Dermatology analysis. Standard treatments work, but they come with tradeoffs that drive people to look for alternatives: benzoyl peroxide commonly causes dryness, irritation, and redness that leads people to stop using it, and dermatologists have grown more cautious about the antibiotics long prescribed for acne because of antimicrobial resistance concerns. That is the gap microbiome-targeted skincare is positioning itself to fill, not by wiping out skin bacteria indiscriminately, but by targeting the acne-associated strains of Cutibacterium acnes (the bacterium most linked to acne inflammation) while leaving the rest of the skin's ecosystem intact.

How the Researchers Screened Five Studies Out of 142 Records

The reviewers followed the PRISMA 2020 reporting standard, searching PubMed, ScienceDirect, and Google Scholar for English-language human studies published between 2020 and 2025 that tested a topical probiotic, postbiotic, probiotic-derived product, or bacteriophage against acne. The search turned up 142 records; after removing 32 duplicates, the team screened 110 titles and abstracts, excluded 78 as off-topic or non-clinical, assessed 32 full texts, and landed on 5 studies that met every eligibility criterion, ranging from a 45-person investigator-blinded trial to a 104-person randomized controlled trial. Two reviewers independently extracted data and rated each study's risk of bias using the Cochrane RoB 1 tool; the overall risk was rated low to moderate, driven mainly by small samples, open-label designs, and incomplete blinding in two of the five trials.

What This Means If You Are Considering a Microbiome-Based Acne Product

For someone managing their own acne, the review's bottom line is that microbiome-targeted topicals look genuinely promising as an add-on or alternative option, particularly if irritation has forced you off benzoyl peroxide or you are trying to avoid another course of antibiotics, but none of these products has been shown to beat standard therapy outright. The L. paracasei-derived lotion came closest, matching benzoyl peroxide's inflammatory-lesion improvement with fewer side effects in a head-to-head trial. It is worth being explicit here: none of these five products is an approved acne drug the way benzoyl peroxide or prescription retinoids are, most are cosmetic-grade formulations tested in small trials, so treat marketing claims about "fixing your microbiome" with skepticism, and talk to a dermatologist before swapping out an existing treatment, especially for moderate-to-severe acne.

The Evidence Rests on Small Samples and Short Follow-Up

The review's authors are explicit that this evidence base comes from only five studies with small to moderate sample sizes, most followed for just three to four weeks, too short to know whether the improvements hold up or whether lesions return after stopping treatment. Differences in how the trials counted lesions, measured sebum, and reported side effects meant the authors could not run a meta-analysis (a pooled statistical combination of results across studies) to generate one overall effect size. Two of the five trials, the LactoSporin study and the L. plantarum pilot, were open-label or uncontrolled pilot designs, which raises the chance that expectation alone shaped what participants and assessors reported. Publication bias is also a live possibility, since small early-phase trials with encouraging results tend to get published more readily than ones that show nothing.

Where Bacteriophage Therapy and Larger Trials Go Next

The review's authors call for larger, multicenter, blinded trials with standardized lesion counts and strain-level microbiome measurements before microbiome-targeted products can be routinely recommended alongside, or instead of, standard acne therapy. One entrant has already moved further down that path: the bacteriophage gel BX001, which uses viruses engineered to infect only C. acnes, significantly reduced facial C. acnes burden in a 75-person phase 1 trial while remaining safe and well tolerated. A larger, 12-week phase 2 study of the same product has since reported that it significantly improved acne-prone skin from baseline but did not outperform a placebo vehicle, a reminder of why the review's authors frame all five of these approaches as preliminary rather than as a green light for routine use.

Common Questions

What is the difference between a probiotic and a postbiotic in these products? A true topical probiotic would contain live bacteria, but none of the five reviewed trials actually tested a strictly live probiotic. A postbiotic, like LactoSporin and the ferment-lysate product studied here, is a preparation of inactive microorganisms, microbial fragments, or their metabolic byproducts that still produces a measurable effect on skin without needing to be alive.

Is it safe to put a bacteriophage gel on your skin? In the one human trial to test it, BX001, a gel containing viruses that infect only Cutibacterium acnes, was reported as safe and well tolerated over four weeks, with only mild or moderate side effects and no serious adverse events.

Should I stop using benzoyl peroxide and switch to a probiotic-based product? Not based on this evidence. The strongest comparative trial found a probiotic-derived lotion produced similar inflammatory-lesion improvement to 2.5% benzoyl peroxide with fewer side effects, but no product in this review was shown to outperform standard therapy, and a dermatologist should weigh in before you change an existing regimen.

How soon could these products be available or prescribed? None of the five are established acne treatments; most are cosmetic-grade formulations still in early clinical testing. The review's authors say larger, longer, blinded trials with standardized endpoints are needed before that changes, per the current acne treatment guidelines that still center benzoyl peroxide, retinoids, and antibiotics as first-line care.

References

1. GI Salsabil, NA Wijaya (2026). Clinical Efficacy and Safety of Topical Microbiome Modulation for Acne Vulgaris: a Systematic Review of Clinical Studies Published between 2020 and 2025. EKSAKTA: Berkala Ilmiah Bidang MIPA. https://doi.org/10.24036/eksakta/vol27-iss04/714
2. Zhou Zhu, Xiaoying Zhong, Zhongyu Luo, et al. (2024). Global, regional and national burdens of acne vulgaris in adolescents and young adults aged 10–24 years from 1990 to 2021: a trend analysis. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae352
3. M. Golembo, S. Puttagunta, U. Rappo, et al. (2022). Development of a Topical Bacteriophage Gel Targeting Cutibacterium Acnes for Acne Prone Skin and Results of a Phase 1 Cosmetic Randomized Clinical Trial. Skin Health and Disease. https://doi.org/10.1002/ski2.93
4. Alicia Podwojniak, Isabella J. Tan, John Sauer, et al. (2024). Acne and the cutaneous microbiome: A systematic review of mechanisms and implications for treatments. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20332